Clinical Trials Logo

Congenital Adrenal Hyperplasia clinical trials

View clinical trials related to Congenital Adrenal Hyperplasia.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT02574910 Suspended - Clinical trials for Congenital Adrenal Hyperplasia

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone. In this Phase 1 study, the investigators will determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels during the 7-day Treatment Period.